Advertisement

Topics

CStone Pharma starts two pivotal phase II studies of anti─PD─L1 monoclonal antibody CS1001

14:50 EDT 14 Jun 2018 | PharmaBiz

CStone Pharmaceuticals has announced that two pivotal phase II studies exploring the efficacy and safety of CS1001 in patients with natural killer cell/T─cell lymphoma (CS1001─201) and classical Hodgkin's lymphoma

Original Article: CStone Pharma starts two pivotal phase II studies of anti─PD─L1 monoclonal antibody CS1001

NEXT ARTICLE

More From BioPortfolio on "CStone Pharma starts two pivotal phase II studies of anti─PD─L1 monoclonal antibody CS1001"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...